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Background: The alanine allele of P12A polymorphism in PPARG gene in a few studies 
has been associated with a reduced or increased risk of acute myocardial infarction (AMI). 
Yet, the risk relation has not been conﬁ  rmed, and data on ischemic stroke (IS) is scarce. We 
therefore investigated the role of this polymorphism on occurrence of AMI, coronary heart 
disease (CHD) and IS.
Methods and ﬁ  ndings: We performed a case-cohort study in 15,236 initially healthy Dutch 
women and applied a Cox proportional hazards model to study the relation of the P12A polymor-
phism and AMI (n = 71), CHD (n = 211), and IS (n = 49) under different inheritance models. In 
addition, meta-analyses of published studies were performed. Under the dominant inheritance 
model, carriers of the alanine allele compared with those with the more common genotype were 
not at increased or decreased risk of CHD (hazard ratio [HR] = 0.82; 95% conﬁ  dence interval 
[CI], 0.58 to 1.17) and of IS (HR = 1.03; 95% CI, 0.14 to 7.74). In addition no relations were 
found under the recessive and additive models. Our meta-analyses corroborated these ﬁ  ndings 
by showing no signiﬁ  cant association. For AMI we found a borderline signiﬁ  cant association 
under dominant (HR = 0.49; 95% CI, 0.26 to 0.94), and additive (HR = 0.51; 95% CI, 0.26 
to 1.00) models which could be due to chance, because of small cases in this subgroup. The 
meta-analysis did not show any association between the polymorphism and risk of AMI under 
the different genetic models.
Conclusions: Our study in healthy Dutch women in combination with the meta-analyses of 
previous reports does not provide support for a role of P12A polymorphism in PPARG gene in MI 
and CHD risk. Also our study shows that the polymorphism has no association with IS risk.
Keywords: genetics, myocardial infarction, polymorphism, PPARG gene, risk factors, popula-
tion-based
Introduction
The most prevalent human PPARG gene mutation is a cytosine to guanine substitu-
tion in exon B (codon 12) of this gene (Knouff and Auwerx 2004), resulting in an 
exchange of proline (P) to alanine (A) at amino acid (Temelkova-Kurktschiev et al 
2004). Initially recognized to play a role only in adipogenesis and glucose homeostasis, 
recent works have shown associations with regulation of cell growth, migration and 
inﬂ  ammation (Schiffrin et al 2003; Youssef et al 2004). Also, PPARG2 has a role in 
insulin signaling, insulin resistance, and development of type 2 diabetes (Memisoglu 
et al 2003).
There is some evidence that P12A polymorphism in PPARG gene is related to 
vascular risk factors (Deeb et al 1998; Altshuler et al 2000; Meirhaeghe et al 2000; 
Masud and Ye 2003; Ostgren et al 2003; Doney et al 2004). A meta-analysis showed Vascular Health and Risk Management 2008:4(2) 428
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a 21% risk reduction for type2 of diabetes (Altshuler et al 
2000). Moreover, A12 allele carriers have signiﬁ  cantly 
higher body mass index (BMI) (Masud and Ye 2003), lower 
insulin resistance (Deeb et al 1998; Meirhaeghe et al 2000) 
and reduced blood pressure (Ostgren et al 2003; Doney et al 
2004). These ﬁ  ndings suggest that a possible role in athero-
sclerosis development. This is supported by recent ﬁ  ndings 
showing a relation of A12A genotype to reduced common 
carotid intima-media thickness (Temelkova-Kurktschiev et al 
2004; Al Shali et al 2004b).
However, information on the relation with acute myo-
cardial infarction (AMI), coronary heart disease (CHD) and 
ischemic stroke (IS) as the clinical endpoints is scarce, and 
inconsistent (Vos et al 2000; Ridker et al 2003; Doney et al 
2004; Tobin et al 2004; Pischon et al 2005; Li et al 2006) for 
CHD. A reduced risk for ischemic stroke has been reported 
(Lee et al 2006). We set out to investigate the relation of 
P12A polymorphism in PPARG gene on occurrence of AMI, 
CHD and ischemic stroke in middle-aged Dutch women. To 
expand the evidence further, we performed meta-analyses 
using published data from observational studies.
Methods
Prospect-EPIC study
Study design, general questionnaire, anthropometric and 
Laboratory measurements have been described in detail 
elsewhere (Zafarmand et al in Press). Brieﬂ  y, the study 
population consisted of participants of the Prospect-EPIC 
cohort. Participants were recruited between 1993 and 1997 
among women living in Utrecht and vicinity who attended 
the regional population-based breast cancer-screening 
program. A total of 17,357 women aged 49–70 were 
included. Follow-up event information was obtained from 
the Dutch Centre for Health Care Information, which holds 
a standardized computerized register of hospital discharge 
diagnoses. Using the International Classiﬁ  cation of Diseases, 
ninth Revision (ICD-9) codes for the main discharge reason, 
we categorized cardiovascular disease (codes 390–459) as 
CHD (codes 410–414), including acute myocardial infarction 
(code 410), as ischemic cerebrovascular disease (codes 
433–435), and other cardiovascular diseases. Whenever 
multiple events occurred, the ﬁ  rst diagnosis was taken as 
endpoint of interest. All women signed an informed consent 
form prior to study inclusion. The study was approved by 
the Institutional Review Board of the University Medical 
Center Utrecht.
We applied the case-cohort design introduced by Prentice 
(1986). In this design, data is collected on all subjects, but 
the data would only be analyzed on cases and sub-cohort 
members. Cases are those emerging in the total cohort; 
controls are subjects in the sub-cohort. The sub-cohort is a 
randomly selected sample of 10% (n = 1736) from the 17,357 
women in the total cohort. Women who did not consent to 
linkage with vital status registries or who were not traceable 
(cases n = 3/sub-cohort n = 38) were not included. Women 
who reported a diagnosis of cardiovascular disease (ICD-
9; 390–459) at baseline, who had missing questionnaires 
or blood or DNA samples were excluded. This resulted in 
15,236 women in the total cohort and 1519 women in the 
sub-cohort at baseline (as the control group). All ﬁ  rst fatal 
and non-fatal CHD and ischemic stroke events that arose 
during follow-up until January 1st 2000 were selected as 
cases. These were 211 CHD cases, including 71 AMIs, and 
49 ischemic cerebrovascular events. For all case subjects 
follow up ended at the date of diagnosis or at the date of 
death due to cardiovascular disease.
Genetic analysis
Genetic analysis was performed at the Cardiovascular Geno-
typing (CAGT) laboratory of the Department of Internal 
Medicine of the University Hospital Maastricht. Genomic 
DNA was extracted from buffy coats with the use of the 
QIAamp® Blood Kit (Qiagen Inc., Valencia, California, 
USA). Genotyping of the polymorphisms was performed 
using a multilocus genotyping assay for candidate markers 
of cardiovascular disease risk (Roche Molecular Systems 
Inc., Pleasanton, CA, USA) (Cheng et al 1999). Genotyping 
was preformed blinded to the case-control status. A random 
double-check was performed to detect potential genotyping 
errors.
Data analysis
To assess the relation of P12A polymorphism with the out-
come, we used a Cox proportional hazards model with an esti-
mation procedure adapted for case-cohort designs. We used 
the unweighted method by Prentice, which is incorporated in 
a SAS macro at http://lib.stat.cmu.edu/general/robphreg.
Baseline characteristics of sub-cohort by genotypes (P12P, 
P12A and A12A) is given. Hardy-Weinberg equilibrium 
(HWE) was evaluated with the χ2 test. Frequencies of A12 
allele and P12 allele were determined. We assessed the 
association between the polymorphism and events under 
different genetic models. The dominant genetic model 
compares individuals with one or more polymorphic alleles 
(P12A and A12A genotypes combined) with a group with 
no polymorphic alleles (P12P). The recessive genetic model Vascular Health and Risk Management 2008:4(2) 429
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compares the A12A genotype with the combined P12P and 
P12A genotypes. The additive genetic model assumes that 
there is a linear gradient in risk between the P12P, P12A 
and A12A genotypes (P12P genotype baseline). This is 
equivalent to a comparison of the A12 allele versus the P12 
allele (baseline). All analyses were performed for AMI, CHD, 
ischemic stroke and total ischemic events. A value of p  0.05 
(2-sided) was considered signiﬁ  cant.
Meta-analysis
Search strategy and data extraction
For the meta-analysis, published data was used concerning 
the P12A polymorphism in PPARG gene and MI, CHD and 
IS. The search was done on November 15, 2006. In addi-
tion, our own data were included. Studies were found with 
PubMed/Medline, ISI Web of Knowledge, and Embase using 
the following text search string: (Pro12Ala OR P12A) AND 
(“Peroxisome proliferator-activated receptor gamma” OR 
PPARG) AND (coronary disease OR coronary heart disease 
OR CHD OR myocardial infarction OR MI OR myocardial 
infarct OR coronary artery disease OR CAD OR ischemic 
heart disease OR IHD OR cardiovascular disease OR heart 
disease OR angina OR ischemic stroke OR CVA OR stroke 
OR cerebrovascular accident). The following constraints 
were applied to the search: (1) only published articles in 
journals or their supplements (English); and (2) studies only 
in human subjects. Manual bibliography review was added. 
This search (done by MHZ and MLB) identiﬁ  ed 36 poten-
tially relevant articles. Studies were included if they reported 
the relative risks, ORs or HRs and 95% conﬁ  dence intervals 
[CIs] for events related to PPARG2 P12A polymorphism or 
provided raw data that allowed estimation of these values. 
We excluded 24 studies because of other endpoints (such as 
vascular risk factors); one repeated publication; one study 
which did not provide sufﬁ  cient data; two review papers; and 
one study with carotid intima-media thickness as endpoint. 
Since only one paper had been found for ischemic stroke, 
we excluded ischemic stroke from the meta-analysis. Hence, 
data were available for these analyses from 8 original reports 
(6 studies found with databases, one additional article identi-
ﬁ  ed by a hand search and our data) involving 2793 cases and 
7680 controls (Table 4). As Pischon and colleagues (2005) 
had provided data from two different studies (Nurses’ Health 
Study [NHS] in women and Health Professionals Follow-up 
Study [HPFS] in men), we consider them in the analysis as 
two studies. The following information was extracted from 
each study: ﬁ  rst author, study design, year of publication, 
geographical location, deﬁ  nition and number of cases and 
controls, mean age of cases and controls, gender, genotype 
frequency, genotyping methods and consistency of genotype 
frequencies with Hardy-Weinberg equilibrium.
Data analysis
For the meta-analysis, Mantel-Haenszel was used as ﬁ  xed 
effects model and the DerSimonian-Laird method was used 
as random-effects model, all under different genetic mod-
els. The Egger’s test with 95% CI was used for evaluating 
publication bias. In each study, we tested for HWE by using 
an asymptomatic χ2 test or an exact test among the controls 
(Trikalinos et al 2006). We used Cochran’s χ2 – based Q 
statistic for between-study heterogeneity (Lau et al 1997), 
which is considered signiﬁ  cant for p  0.10, as well as the 
I  2 statistic for estimation of inconsistency in meta-analyses. 
I  2 represents the percentage of the observed between-study 
variability due to heterogeneity rather than to chance and 
ranges from 0 to 100 percent where a value of 0% indicates 
no observed heterogeneity, and larger values an increasing 
degree of heterogeneity. Values above 75 percent imply high 
heterogeneity (Higgins et al 2003). Meta-analysis was carried 
out using STATA 9.1.
Results
Prospect-EPIC study results
General characteristics of the randomly sampled participants 
of the cohort (n = 1519) are given in Table 1. Of the partici-
pants 1143 (75.2%) had the common type allele (P12P), 346 
(22.8%) were heterozygous for the A12 allele (P12A), and 
30 (2%) were homozygous for the A12 allele. The genotype 
distribution was in HWE.
None of conventional risk factors were statistically 
signiﬁ  cantly related to the P12A polymorphism (Table 1). 
Median follow up time for the sub-cohort was 4.3 years, with 
a total of 6,525 person years. The actual follow-up in the 
baseline cohort of 15,236 women was 64,768 person years. 
Due to the case-cohort design, 23 women in the sub-cohort 
eventually were CHD cases and 5 of them were ischemic 
stroke cases (totally 28 cases). Clinical characteristics of 
CHD cases and controls are presented in Table 1.
Comparing allele frequencies in cases and control groups 
separately did not show signiﬁ  cant difference between them, 
except for myocardial infarction, which showed a borderline 
signiﬁ  cant relation (Table 2).
A lower risk of AMI with only borderline effects was 
found under dominant (OR = 0.51; 95% CI, 0.26 to 1.00; 
p = 0.05) and additive models (OR = 0.49; 95% CI, 0.26 
to 0.94; p = 0.03) but not under recessive inheritance mode Vascular Health and Risk Management 2008:4(2) 430
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sub-cohort (N = 1519) p-valueb CHD cases Sub-cohort p-valuec
P12P P12A A12A
N total 1143 346 30 - 211 1519 -
Age at intake (yr)a 57.2 ± 6.1 57.1 ± 6.0 56.1 ± 5.4 0.63 60.5 ± 5.9 57.1 ± 6.1 0.01
Body mass index (kg/m2)a 25.8 ± 3.9 25.8 ± 4.1 26.4 ± 3.6 0.69 26.8 ± 3.9 25.8 ± 4.0 0.01
Weight (kg)a 69.5 ±11.2 69.9 ±11.8 72.7 ±11.6 0.28 71.1 ± 11.3 69.7 ± 11.3 0.08
Height (cm)a 164.2 ± 6 164.5 ± 5 165.8 ± 6 0.24 162.8 ± 6 164.3 ± 6 0.01
Waist to hip ratioa 0.78 ± 0.05 0.78 ± 0.05 0.79 ± 0.06 0.56 0.81 ± 0.06 0.79 ± 0.06 0.01
Hypertension (%)d 34.6 29.8 33.3 0.25 51.7 33.4 0.01
Systolic blood pressure (mm Hg)a 133.1 ± 20.2 131.3 ± 19.3 132.9 ± 19.5 0.35 143.3 ± 22.3 132.7 ± 20.0 0.01
Diastolic blood pressure (mm Hg)a 79.1 ± 10.6 78.7 ± 10.5 79.8 ± 10.6 0.80 81.6 ± 10.7 79.0 ± 10.6 0.01
Presence of diabetes (%) 2.3 2.0 3.3 0.88 5.7 2.2 0.01
Presence of hypercholesterolemia (%) 4 4 0 0.53 11.4 3.9 0.01
Current alcohol consumption (%) 87.9 88.3 88.9 0.97 80.9 88.0 0.01
Smoking status (%) Past 34.6 35.3 33.3 0.96 26.1 34.8 0.01
Current 23.1 21.4 33.3 0.31 34.1 22.9 0.01
Pack- yearse 6.8 ± 9.5 6.1 ± 9.1 7.9 ± 11.3 0.38 9.8 ± 11.4 6.7 ± 9.5 0.01
Total cholesterol (mmol/L)a 5.9 ± 1 5.8 ± 1 5.9 ± 1.1 0.14 6.4 ± 1 5.9 ± 1 0.01
HDL cholesterol (mmol/L)a 1.6 ± 0.4 1.6 ± 0.4 1.5 ± 0.4 0.70 1.4 ± 0.3 1.6 ± 0.4 0.01
LDL cholesterol (mmol/L)a 3.9 ± 0.9 3.9 ± 0.9 4.0 ± 1.1 0.28 4.4 ± 1 3.9 ± 0.9 0.01
Serum glucose (mmol/L)a 4.5 ± 1.4 4.5 ± 1.5 4.2  ± 1.5 0.31 5.1 ± 2.5 4.5 ± 1.4 0.01
Notes: aMean ± standard deviation; bComparison of risk factors across genotypes, using the ANOVA F test (continuous variables) and the χ2 statistic (categorical variables); 
cComparison of risk factors across disease status, using the independent samples t-test (continuous variables) and the χ2 statistic (categorical variables); dDeﬁ  ned as a systolic 
blood pressure 140 mm Hg and/or diastolic blood pressure 90 mm Hg and/or questionnaire positive; eThe number of packs of cigarettes smoked per day by the number 
of years the person has smoked.
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; CHD, coronary heart disease (ICD 410–414). 
Table 1 Baseline characteristics of the sub-cohort according to genotype, and clinical characteristics of CHD cases and controls in 
the Prospect – Epic cohort
Table 2 Genotype and allele frequencies of the polymorphism among AMI, CHD, and ischemic stroke cases and sub-cohort of the 
Prospect – Epic cohort
Genotype/allele Acute myocardial infarction Coronary heart disease Ischemic stroke Sub-cohort
No. % No. % No. % No. %
No. of subjects 71 211 49 1519
Genotype 
P/P 61 85.9 167 79.1 38 77.6 1143 75.2
P/A 10 14.1 41 19.4 10 20.4 346 22.8
A/A 0 0.0 3 1.4 1 2 30 2
Allele
Pro 132 93.0 375 88.9 86 87.8 2632 86.6
Ala 10 7.0 47 11.1 12 12.2 406 13.4
χ2 = 4.77 χ2 = 1.61 χ2 = 0.10
Df = 1 df = 1 df = 1
p = 0.03 p = 0.20 p = 0.75Vascular Health and Risk Management 2008:4(2) 431
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(Table 3). The analyses were repeated for CHD and ischemic 
stroke as primary outcomes and also for all ischemic events 
(CHD and ischemic stroke). No statistically signiﬁ  cant 
association was seen for risks of CHD and ischemic stroke 
(Table 3). None of the risk factors was statistically signiﬁ  -
cantly associated with genotypes (Table 1) and we did not 
consider them as confounders in our data. The rationale for 
not adjusting for the risk factors is that we did not want to 
adjust in a primary analysis for intermediates in a potential 
causal pathway and that because genes are randomly assigned 
at conception (Mendelian randomization) confounding by 
lifestyle related factors (or intermediate phenotypes) should 
not be a problem in genetic epidemiology studies (Smith and 
Ebrahim 2004).
We examined the interaction between the P12A poly-
morphism and risk factors for each of the events separately 
by introduction of risk factor*A12 allele carriers term in 
the logistic regression models. No signiﬁ  cant interactions 
between P12A and risk factors in AMI, CHD and total isch-
emic events were seen, apart from smoking (current) and A12 
allele carriers (P = 0.027). In the light of the many associa-
tions we studied, this may actually be a chance ﬁ  nding.
Meta-analysis results
Table 4 shows the characteristics of studies included in 
this meta-analysis. The genotype frequencies in the stud-
ies were consistent with HWE. The meta-analyses did not 
show a signiﬁ  cant association under dominant genetic 
model (OR = 0.85; 95% CI, 0.61 to 1.17; p = 0.32), reces-
sive model (OR = 1.37; 95% CI, 0.77 to 2.47; p = 0.29) 
and additive model (OR = 0.94; 95% CI, 0.72 to 1.25; 
p = 0.69) (Figure 1). Furthermore, pooled estimate 
(Figure 2) did not show a signiﬁ  cant association between 
the polymorphism and CHD, under dominant genetic model 
(OR = 0.99; 95% CI, 0.79 to 1.23; p = 0.92), recessive model 
(OR = 1.40; 95% CI, 0.94 to 2.08; p = 0.10) and additive 
model (OR = 1.04; 95% CI, 0.87 to 1.25; p = 0.64). There 
was evidence for heterogeneity under dominant and addi-
tive genetic models for MI (p = 0.002, p = 0.006) and CHD 
(p = 0.002, p = 0.01), respectively. To deal with heterogene-
ity we used random-effect model (the DerSimonian-Laird 
method) for pooling data. There was not evidence for 
signiﬁ  cant publication bias (Egger’s test = 1.85; 95% 
CI, –4.86 to 8.56; p = 0.54).
Discussion
In this prospective study among healthy Dutch women aged 
49 to 70 years, no statistically signiﬁ  cant association for 
exchanging proline with alanine in PPARG gene was seen 
with CHD and ischemic stroke risk under different genetic 
models. We found a borderline effect for AMI risk under 
the dominant and additive models, which could be a chance 
ﬁ  nding. In the meta-analyses of published observational 
studies we did not ﬁ  nd any signiﬁ  cant association for the 
polymorphism and AMI and CHD risks under different 
inheritance models.
In this study, prevalent cases of CHD and cerebrovascu-
lar disease were excluded to prevent introducing bias due 
to potentially selective survival. The Prospect study is a 
population-based cohort, which makes it less susceptible 
to selection bias. Additional strengths are the comprehen-
sive data and sample collection, complete hospital admis-
sion and mortality follow-up, and the case-cohort design 
which combines the advantages of cohort studies (multiple 
outcomes and time-dependent covariates) with those of 
case-control analyses (fewer subjects), thus being more 
efﬁ  cient. Since the genotypes were in the Hardy-Weinberg 
equilibrium, we did not have misclassiﬁ  cation of exposure 
(genotypes). Limitations are the relative short period of 
follow-up and the relative small number of cases. The 
latter in general reduces the power to show a statistical 
signiﬁ  cant relations.
A new aspect is that we conducted meta-analyses on the 
relation between the P12A polymorphism and MI, CHD and 
ischemic stroke under different genetic models. Yet, due to 
Table 3 Hazard ratios of cardiovascular events under different 
genetic models for P12A polymorphism in PPARG gene in the 
Prospect – Epic cohort
Different   Inheri-   Hazard   95% CI  p-value
events tance  ratio
 Model
Acute  Dominant 0.51  0.26−1.00 0.05
myocardial Recessive  0.34  0.00−2.68 0.47
infarction  Additive 0.49  0.26−0.94 0.03
Coronary  Dominant 0.82  0.58−1.17 0.27
heart disease  ecessive  0.72  0.22−2.37 0.58
  Additive 0.81  0.59−1.12 0.20
Ischemic   Dominant 0.90  0.46−1.78 0.77
stroke  Recessive 1.03  0.14−7.74 0.97
 Additive  0.90  0.49−1.67 0.75
All ischemic   Dominant 0.85  0.62−1.17 0.31
events  Recessive 0.78  0.27−2.22   0.63
 Additive  0.83  0.62−1.11 0.21Vascular Health and Risk Management 2008:4(2) 432
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the genotype frequency, its power is limited for most studies 
especially under recessive genetic model. The results of these 
meta-analyses indicate no association between the poly-
morphism and risk of MI and CHD under different genetic 
models. However it must be noted that an important issue in 
every meta-analysis is publication bias as negative studies 
are less likely to be submitted or accepted for publication, 
especially when this concerns smaller studies. Although 
publication bias was not present based on Egger’s test, the 
performance of this test and the usual funnel plot have been 
challenged (Peters et al 2006) and so we can not completely 
rule out low probability for missing of small negative studies. 
MA for MI risk under the recessive genetic model
Odds ratio
0.1 0.2 0.5 1 2 5 10
Study
 Odds ratio
 (95% CI)
 2.05 (1.00, 4.20) Vos et al.
 0.77 (0.32, 1.86) Ridker et al.
 2.33 (0.73, 7.48) Tobin et al.
 0.57 (0.03, 11.95) Li et al.
 0.34 (0.02, 5.64) Zafarmand et al.
 1.37 (0.77, 2.47) Overall (95% CI)
Odds ratio
0.1 0.5 1 2 5 10
 Combined
 Doney et al.
 Zafarmand et al.
 Li et al.
 Tobin et al.
 Ridker et al.
 Vos et al.
MA for MI risk under the additive genetic model
Odds ratio
0.2 0.5 1 25
Study
 Odds ratio
 (95% CI)
 1.18 (0.92, 1.50)  Vos et al.
 0.79 (0.63, 0.99)  Ridker et al.
 0.87 (0.67, 1.14)  Tobin et al.
 1.69 (1.00, 2.85)  Li et al.
 0.49 (0.26, 0.94)  Zafarmand et al.
 0.94 (0.72,1.25)  Overall (95% CI)
Figure1 Meta-analyses of AMI risk under the different genetic models. These forest plots show the overall odds ratio for 6 studies included in the meta-analysis under 
the dominant, recessive, and additive models respectively. Doney and colleagues (2004) did not provide data for recessive and additive models. Size of cubes represents weight 
of each study.Vascular Health and Risk Management 2008:4(2) 434
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MA for CHD risk under the additive genetic model
Odds ratio
0.5 0.75 1 1.5 2
Study
 Odds ratio
 (95% CI)
 0.97 (0.56, 1.67)  Bluher et al.
 1.69 (1.00, 2.85)  Li et al.
 1.19 (0.85, 1.67)  Pischon et al.(NHS study)
 1.41 (1.02, 1.97)  Pischon et al.(HPFS study)
 0.81 (0.59, 1.12)  Zafarmand et al.
 0.87 (0.67, 1.14)  Tobin et al.
 1.18 (0.92, 1.50)  Vos et al.
 0.79 (0.63, 0.99)  Ridker et al.
 1.04 (0.87, 1.25)  Overall (95% CI)
MA for CHD risk under the dominant genetic model
Odds ratio
0.1 0.2 0.5 1 2 5 10
 Combined
 Ridker et al.
 Vos et al.
 Tobin et al.
 Zafarmand et al.
 Pischon et al.(HPFS study)
 Pischon et al.(NHS study)
 Li et al.
 Bluher et al.
 Doney et al.
MA for CHD risk under the recessive genetic model
Odds ratio
0.1 0.2 0.5 1 25 1 0
Study
 Odds ratio
 (95% CI)
 1.64 (0.30, 9.09)  Bluher et al.
 0.57 (0.03, 11.95)  Li et al.
 1.33 (0.37, 4.74)  Pischon et al.(NHS study)
 2.02 (0.50, 8.16)  Pischon et al.(HPFS study)
 0.72 (0.22, 2.37)  Zafarmand et al.
 2.33 (0.73, 7.48)  Tobin et al.
 2.05 (1.00, 4.20)  Vos et al.
 0.77 (0.32, 1.86)  Ridker et al.
 1.40 (0.94, 2.08)  Overall (95% CI)
Figure 2 Meta-analyses of CHD risk under the different genetic models. These forest plots show the overall odds ratio for 9 studies included in the meta-analysis 
under the dominant, recessive, and additive models respectively. Doney and colleagues (2004) did not provide data for recessive and additive models. Size of cubes represents 
weight of each study.Vascular Health and Risk Management 2008:4(2) 435
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Another limitation may be that our meta-analysis was based 
on published results and that we did not have access to origi-
nal individual data. Finally, the case control studies included 
in the meta-analysis could be potentially prone to selection 
bias if survival post-MI varies by genotype.
The Physician’s Health Study (Ridker et al 2003) reported 
a modest protective effect of P12A polymorphism in PPARG 
gene for incidence of AMI among 523 individuals who subse-
quently developed myocardial infarction and 2092 individuals 
who remained free of reported cardiovascular disease in a 
prospective cohort of 14916 initially healthy American white 
men (Physician’s Health Study cohort) aged 40 to 84 years 
over a mean follow-up period of 13.2 years. The Ala12 allele 
was associated with 23% reduction in myocardial infarction 
risk (OR 0.77; 95% CI, 0.60 to 0.98). In a recent case-control 
study of 844 subjects including 218 patients, increased risk of 
MI was seen under dominant mode of inheritance (OR 1.83; 
95% CI, 1.06–3.1) (Li et al 2006). Under dominant and addi-
tive modes of inheritance we found a statistically signiﬁ  cant 
association (p = 0.05 and 0.03, respectively) for risk of AMI, 
but it must be considered that the number of AMI cases was 
71. Since it has been documented that very large sample 
sizes are required to provide sufﬁ  ciently precise estimates of 
genotype–disease associations (Smith and Ebrahim 2004), the 
power in our study was low (under 20%) which means that the 
probability for having a false positive ﬁ  nding was around 80%. 
Therefore, we conducted a meta-analysis of 6 studies with 1739 
AMI cases and 5903 controls to obtain a more precise estimate. 
The meta-analysis did not show a signiﬁ  cant association under 
dominant, recessive and additive genetic models. Moreover, in 
a very recent prospective population-based study of multi-locus 
candidate gene polymorphisms by a group of investigators who 
had previously published a part of their results (Ridker et al 
2003), showed that neither these three polymorphisms nor the 
others were predictors of MI (Zee et al 2006).
Our ﬁ  ndings with respect to CHD are in accordance 
with results from Nurses’ Health Study and Health 
Professionals Follow-up Study respectively in women and 
men of 245 cases of nonfatal MI or fatal CHD in women 
(compared with 485 controls) and 250 in men (compared 
with 502 controls) during 8 and 6 years of follow-up that 
the P12A polymorphism is not associated with decreased 
risk of CHD (Pischon et al 2005). In a cross-sectional 
study of patients with diabetes mellitus type 2 in Germany 
(in 201 patients with and 164 without CHD) that the A12 
allele was not related to CHD risk (Bluher et al 2002). 
Our ﬁ  ndings and the meta analyses ﬁ  ndings agree with 
these ﬁ  ndings.
Recently, P12A polymorphism has been related to a 
reduced risk for ischemic stroke in patients with type 2 
diabetes (Lee et al 2006). We found no association between 
the polymorphism and risk of occurrence of ischemic stroke 
under different genetic models. As these two studies are the 
only ones available, further studies are needed.
In conclusion, this study in healthy women free from 
previous cardiovascular disease and the meta-analyses show 
that, the P12A polymorphism in PPARG gene is not associ-
ated with future risk of AMI, CHD, and ischemic stroke.
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